摘要
咳嗽变异性哮喘(CVA)是以咳嗽为唯一或主要临床表现的特殊类型的哮喘,其发病机制及病理生理与典型哮喘相似,两者均以持续气道炎症、气道高反应性和气道重构为特点,平均约有30%的CVA患儿最终发展为典型哮喘。白三烯(LTs)是体内重要的炎症介质,LTs及其拮抗剂在CVA的发病和治疗中起重要作用。在CVA的治疗对策中,早期干预具有重要临床意义,在众多合理、有效的指导与治疗选项中,LTs拮抗剂不失为一项有效、安全的选择。该文就CVA与LTs关系的研究进展作一综述。
Cough variant asthma （CVA） is a special asthma presenting chronic cough as the main or only clinical symptom. It is similar of the pathogenesis and pathology ＆ physiology of CVA and classial asthma （CA）. The common characteristic of CVA and CA are persistent airway inflammation, airway hyperrespensiveness and airway remodeling. An average of about 30% of pediatric patients with CVA eventually develop into CA. Leukotriene （LTs） is one of important inflammatory mediators in vivo. LTs and its antagonist （LTRAs） play an important role in the pathogenesis and treatment of CVA. Early intervention is clinic important for countermeasure about treatment of CVA. LTPAs is a safe and effective choice. This paper reviewed the research progress on the relation between CVA and LTs.
出处
《中国临床新医学》
2013年第1期87-90,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
咳嗽变异性哮喘
白三烯
治疗
Cough variant asthma（CVA）
Leukotriene （LTs）
Therapy
